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Abstract: Alzheimer’s disease is the most common cause of dementia in older adults. The 
clinical features include progressive memory decline as well as cognitive deficits with execu-
tive dysfunction, language, visual perceptual difficulties, apraxia and agnosia. During the 
moderate to severe stage of the disease, there is a major decline in memory and function, while 
neuropsychiatric disturbances often emerge and patients become difficult to manage. These 
distressing symptoms increase caregiver burden and add to the direct costs of care of the patients. 
Any improvements in patient function and behavioral symptoms can reduce caregiver burden. 
Memantine has been available for a number of years in Europe and in North America. In this 
article, we examine the pharmacological rationale for its use, and the current clinical evidence 
for its efficacy and long-term effectiveness in the management of cognitive and behavioral 
symptoms in moderate to severe stages of Alzheimer’s disease.
Keywords: memantine, Alzheimer’s disease, dementia
Introduction
Alzheimer’s disease (AD) is an incurable neurodegenerative disorder and the most 
common cause of dementia in older adults. In the Canadian Study of Health and 
Aging (CSHA), it was estimated that AD accounted for 75% of all dementias.1 The 
clinical features include progressive and relentless decline in memory and other 
cognitive spheres such as executive dysfunction, language problems, visual perceptual 
difficulties, apraxia and agnosia, as well as neuropsychiatric disturbances.2 During 
the moderate to severe stage of AD, major decline in memory, function and behavior 
become evident. In turn, patients at this stage often become an enormous burden 
on caregivers, as well as a huge strain on the cost of health care for the society. Any 
improvements in patient function and relief from caregiver burden will significantly 
affect the health and well-being of both the patients and their family.
The pathological hallmarks of AD are the presence of neuritic plaques and 
neurofibrillary tangles. The composition of the senile plaques include amyloid beta 
peptide (Aβ), apolipoprotein E, α1-antichymotrypsin, sulfated glycosaminoglycans, 
and complement factors, while the mature plaques may also contain ubiquitin, 
phosphorylated tau, and chromogranin-A.3,4 A number of molecular, genetic, and 
clinical studies suggest that Aβ oligomers from amyloid precursor protein is the pivotal 
initiation step in AD pathogenesis, and is responsible for synaptic impairment in neu-
ronal degenaration.5 Based on the amyloid cascade hypothesis, the formation of Aβ 
oligomers can interfere directly with memory formation, and trigger a host of secondary Neuropsychiatric Disease and Treatment 2009:5 554
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processes including tau hyperphosphorylation, neurofibrillary 
tangles formation, synaptic degradation, excitotoxicity, 
oxidative injury, inflammation, demyelination, and eventual 
neuronal cell death.4 While the accumulation of amyloid is 
felt to be the main inciting factor of AD pathogenesis, the 
correlation between the formation and disposition of neuritic 
plaques and the clinical presentation of cognitive impairment 
remains unclear.6
As the disease progress, cholinergic and glutamateric 
neurotransmission decline. The currently approved AD 
treatments are aimed at improving neurotransmission in 
the remaining neurons, which include the cholinesterase 
inhibitors (ChEIs) and an N-methyl-D-aspartate (NMDA) 
antagonist, memantine. In this article, we examine the current 
evidence on efficacy of memantine and evaluate its impact 
on the long-term treatment in moderate to severe AD.
Methods
A literature review was performed by PubMed and EMBASE 
databases search. The following search terms were used in 
combination: Alzheimer’s disease, moderate to severe, and 
randomized, controlled, trials, and RCT (accessed June 2009). 
Four RCTs examining the effects of memantine in moderate 
to severe AD were identified. While no RCT was longer than 
28 weeks in duration, one had a follow-up extension phase 
for up to 52 weeks. A number of post-hoc analyses of the 
clinical trials have also been published. The results of these 
studies are summarized in Table 1. In addition, we examined 
the findings from a clinical effectiveness observational study 
with a mean follow-up duration of 30 months. We also 
reviewed the mechanism of action of memantine on AD and 
its clinical pharmacokinetic properties in human studies.
Mechanism of action
The rationale for memantine’s use in treatment of AD is based 
on the glutamate hypothesis.7,8 Glutamate is one of the main 
excitatory neurotransmitters in the central nervous system 
(CNS) and is involved in memory and learning.9 Glutamate 
actions are counterbalanced by gamma-amino-butyric acid 
(GABA) which is the major inhibitory neurotransmitter in the 
CNS. It is hypothesized that high concentrations of glutamate 
cause an excess calcium influx through the ion channel that 
leads to excitotoxicity.10 It has been shown in AD patients 
that glutamate transporters in glial cells are reduced, while 
the presence of beta amyloid indirectly stimulates exces-
sive glutamate production.11 This phenomenon is thought to 
contribute to the neurotoxicity of beta amyloid and eventual 
neuronal cell death in AD.12 The excitotoxicity is mediated 
through N-methyl-D-aspartate (NMDA) receptors via 
increased selective permeability to calcium.
Memantine is a low to moderate affinity, uncompetitive 
NMDA receptor antagonist as well as a partial agonist of 
the NMDA receptor, which blocks the NMDA receptor 
channel in a use-dependent fashion. At lower concentration, 
memantine continues to allow the physiological synaptic 
signal to be recognized, while at a higher concentration, 
it blocks the pathological effect of excessive glutaminergic 
stimulation. This dual mechanism may allow memantine 
to act as a neuroprotective agent against excitotoxicity as 
well as an enhancer of synaptic integrity.9 Moreover, recent 
studies on animal models suggest that NMDA receptor 
induced neurotoxicity may be linked to neurofibrillary 
tangle mediated degeneration in AD.13 In addition, since 
Aβ deposits can act as an inflammatory stimulus to activate 
glial cells to release cytokines and trigger a cascade of toxic 
processes and resultant overactivation of NMDA receptors, 
inhibition of excessive glutaminergic excitation by meman-
tine may also delay disease progression by inhibiting the 
inflammatory cascade.14–16 Recent studies in mice suggest 
that minimizing NMDA receptor activation during the early 
stages of chronic neuroinflammation can reduce glial cells 
activation and improve spatial memory deficits.17 These pre-
clinical studies suggest that treatment with NMDA receptor 
antagonist may, in part, diminish cognitive decline by limiting 
neuroinflammation.
Memantine is currently the only NMDA receptor 
antagonist that is well tolerated in human clinical studies, 
and has been approved by the European Agency for the 
Evaluation of Medicinal Products (EMEA) and the US Food 
and Drug Administration (FDA) for treatment of moderate 
to severe AD.
Pharmacokinetics of memantine
Memantine is well absorbed by oral administration. Peak 
plasma concentration is reached between 3 and 7 hours, with 
a low plasma protein binding fraction (45%). Food has no 
effect on its absorption.18 Memantine has a linear pharma-
cokinetic pattern which can be achieved in approximately 
3 weeks. The majority of ingested memantine is excreted 
via urine in unchanged form, with the reminder converted 
to 6-hydroxy-memantine, 1-nitroso-deaminated memantine 
and memantine N-glucuronide conjugate. These polarized 
metabolites have no significant clinical effects. The hepatic 
microsomal cytochrome P450 system, including CYP2A6, 
CYP2C9, CYP2D6, CYP2E1, CYP3A, and CYP1A2, 
have no significant role in the metabolism of memantine.19 Neuropsychiatric Disease and Treatment 2009:5 555
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The combination of donepezil and memantine does not alter 
its pharmacokinetics nor pharmacodynamics.20 No dosage 
adjustment is needed in patients with mild to moderate 
hepatic impairment, but caution is recommended in severe 
hepatic impairment since no data on its pharmacokinetics 
have been reported. The recommended starting dose of 
memantine is 5 mg daily. The dose can be increased gradually 
to 10 mg twice daily by adding 5 mg per week.2 No dosage 
Table 1 results of randomized controlled trials in moderate to severe Alzheimer’s disease
Study Number 
of patients 
(treatment/
placebo)
Mean 
MMSE 
at baseline
Follow-up Outcomes 
measures
Main conclusion References
MeM-MD-01 
(memantine vs placebo)
178/172 10 24 wks SiB, NPi, ADCS-
ADLsev CiBiC+, 
BGP BGP-care, FAST
Significant advantage with 
Memantine on the SiB and 
CiBiC+ at 12 and 18 weeks, 
but no significant difference 
at 24 wks
van Dyck 
et al24
MeM-MD-02 (memantine plus   
donepezil vs placebo plus 
donepezil)
203/201 10 24 wks ACDS-ADLsev 
CiBiC+, SiB, NPi, 
BGP-care
Memantine plus donepezil 
showed significant benefits 
in all measures compared to 
placebo plus donepezil
Tariot et al23
Post-hoc analysis of responders: MeM-MD-02 ACDS-ADLsev 
CiBiC+, SiB, NPi
responder analyses show an 
NNT of 8–10, and memantine 
produces both clinically 
important improvement and 
stabilization of symptoms
van Dyck 
et al41
Post-hoc analysis of cognitive effects: MeM-MD-02 SiB Beneficial cognitive effects on 
memory, language, and praxis 
with memantine treatment
Schmitt et al42
Post-hoc analysis of behavioral effects: MeM-MD-02 NPi Memantine reduced agitation/
aggression, irritability, and 
appetite/eating disturbances
Cummings 
et al43
Post-hoc analysis of functional outcome: MeM-MD-02 ADCS-ADL Memantine showed benefits 
on function with grooming, 
toileting, conversing, watching 
TV, and being left alone
Feldman 
et al44
Memantine vs placebo 126/126 8 28 wks ACDS-ADLsev 
CiBiC+, SiB, NPi, 
MMSe, FAST, GDS
Memantine had better 
outcome on ACDS-ADL, 
CiBiC+ and SiB
reisberg 
et al22
24-wk open-label extension 
of the 28-wk rCT
52 wks ACDS-ADLsev 
CiBiC+, SiB, NPi, 
MMSe, FAST, GDS
Patients who switched from 
placebo to memantine had 
improvements in all efficacy 
measures (relative to rate of 
decline in placebo phase)
reisberg 
et al36
Post-hoc analysis of functional 
disability in the 28-wk rCT
28 wks ACDS-ADLsev Memantine-treated patients 
were 3 times more likely to 
remain autonomous
rive et al40
Post-hoc health economic 
analysis of the 28 wk rCT
28 wks rUD resource utilization and total 
health costs were lower in 
the memantine treated group
Wimo et al39
9M-Best study 
(memantine vs placebo)
82/84 6 12 wks CGi-C, BPG, 
BPG-care, Ferm’s 
D-scale
Significant improvement in 
CGi-C and BPG favoring 
memantine treatment
Winblad and 
Poritis21
Abbreviations: ADCS-ADLsev,   Alzheimer’s Disease cooperative Study   Activities of Daily Living Scale – a modified version for severe   AD patients; BGP (BPG-care), Behavior 
rating Scale for Geriatric Patients (BPG-care = BPG-care dependency subscale); CGI-C, Clinical Global Impression-change; CIBIC+, Clinician’s interview Based impression 
of Change with caregiver input; FAST, Functional   Assessment Staging   Tool; GDS, Global Deterioration Scale; MMSE, Mini Mental State Examination; NPI, Neuropsychiatric 
Inventory; RUD, Resource Utilization in Dementia scale; SIB, severe impairment battery.Neuropsychiatric Disease and Treatment 2009:5 556
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adjustment is needed in patients with mild to moderate renal 
impairment; however, a decreased dosage to 10 mg once daily 
is recommended in patients with severe renal impairment.19
Randomized control trials 
of memantine in moderate 
to severe AD
Four double-blind randomized controlled trials (RCT) 
of memantine in patients with moderate to severe AD 
were retrieved from PubMed search (last accessed 
8 June 2009).21–24 The findings of the RCTs are summarized 
in Table 1. The first RCT, 9M-BEST (Benefit and Efficacy 
in Severely Demented Patients during Treatment with 
Memantine) study, was a multicenter study conducted in 
Latvia.21 One hundred and sixty-six patients were randomized 
to receive either memantine 10 mg per day or placebo for 
12 weeks. It included patients with AD and vascular dementia 
with an age range between 60 to 80 years. Dementia was 
diagnosed by DSM-III-R criteria.25 Other inclusion criteria 
included Mini-Mental State Examination (MMSE) score 
of 10 (average = 6), Global Deterioration Scale (GDS) 
stages between 5 and 7, and a duration of dementia of at least 
12 months.26 The primary end points were the Clinical Global 
Impression of Change (CGI-C) rated by clinicians, and the 
care dependency subscale of the Behavioral Rating Scale for 
Geriatric Patients (BGP) rated by nursing staff. Secondary 
end points included the Ferm’s D-test, the Clinical Global 
Impression of severity of illness (CGI-S), and the BGP total 
score.27 A significantly greater percentage of patients was 
improved on CGI-C in the memantine group compared to 
placebo (73% vs 42%, P  0.001). There was also signifi-
cant benefit with memantine on the BPG care dependency 
subscale. Secondary end point analysis of CGI-S results were 
also superior in the memantine group (78% vs 53% P = 0.016), 
and significant behavioral improvements were demonstrated 
on every item of the Ferm’s D-test.
In a longer-term study, Reisberg et al reported the results 
of a 28-week, double-blind ,multicenter RCT conducted in 
the US.22 Two hundred and fifty-two patients with moderate 
to severe AD by DSM-IV criteria were randomized to 
receive memantine versus placebo.28 Inclusion criteria 
included an MMSE score of 3 to 14, GDS stage of 5 or 6, 
and a stage of 6a or higher on the Functional Assessment 
Staging instrument (FAST).29 The primary outcome meas-
ures were the Clinician’s Interview-Based Impression of 
Change Plus Caregiver Input (CIBIC-Plus) at 28 weeks, 
and the Alzheimer’s disease Cooperative Study Activities of 
Daily Living Inventory modified for more severe dementia 
(ADCS-ADLsev).30–32 Using an intention-to-treat analysis 
(ITT) with last observation carried forward (LOCF), a trend 
favoring memantine treated patients (P = 0.06) was shown 
in the CIBIC-Plus, while analysis based on observed cases 
demonstrated statistically significant benefits (P = 0.03). 
The ADCS-ADLsev also showed significantly better scores 
with memantine (P = 0.02). Secondary outcome measures 
in this study included the Severe Impairment Battery (SIB), 
MMSE, GDS, FAST, the Neuropsychiatric Inventory (NPI), 
and the Resource Utilization in Dementia (RUSP).33–35 
Memantine-treated patients had significant better scores 
than placebo on the SIB (P = 0.002) as well as the FAST 
(P = 0.007). However, there were no statistically significant 
differences on the secondary measures of MMSE, GDS, and 
NPI. In the RUSP analysis, caregivers were able to spend 
45.8 hours per month less when caring for patients receiving 
memantine compared to placebo (P = 0.01). This 28-week 
RCT was followed by a 24-week open-label extension 
phase.36 When the 80 patients who were initially treated with 
placebo received memantine 20 mg daily during this 24-week 
extension, they had a significantly slower rate of decline on 
the CIBIC-Plus (P  0.01), ADCS-ADL (P = 0.021), and 
the SIB (P = 0.049). Limitations of this study include a high 
exclusion rate (27%) and a high dropout rate (28%), which 
raises questions on the generalizability of the results and the 
clinical relevance of the relatively small, although statistically 
significant, improvements in the outcome measures.37,38
Two post-hoc analyses were derived from this study. 
In a cost analysis by Wimo et al, it was demonstrated that 
resource utilization and total health costs were lower in the 
memantine-treated group compared to placebo.39 Further 
analysis of resource utilization showed that caregiver time 
for patients receiving memantine was significantly less than 
those receiving placebo (difference of 51.52 hours per month; 
95% CI –95.27, –7.17). An analysis of total caregiver costs 
and total societal costs also favored memantine. Another 
post-hoc analysis by Rive et al focused on activities of daily 
living.40 It was found that patients treated with memantine 
were three times more likely (odds ratio [OR] = 3.03; 95% 
confidence interval [CI] = 1.38, 6.66) to remain autonomous 
after 6 months than those on placebo.
In the third RCT reported by Tariot et al (MEM-MD-02), 
the effectiveness of augmentation therapy with memantine 
combined with donepezil was examined.23 Four hundred and 
four patients with a diagnosis of moderate to severe AD (based 
on the National Institute of Neurological and Communicative 
Disorders and Stroke – Alzheimer Disease and Related Neuropsychiatric Disease and Treatment 2009:5 557
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Disorders Association criteria (NINCDS-ADRDA)) who 
had been stable on donepezil for at least 6 months with 
an MMSE score of 5 to 14 were randomized to receive 
memantine with donepezil versus placebo with donepezil for 
24 weeks. The primary outcome measures were the change 
on the SIB and the ADCS-ADLsev. There was a statisti-
cally significant benefit of memantine treatment on the SIB 
(P = 0.01) as well as ADCS-ADLsev (P = 0.03). All of the 
secondary measures with CIBIC-Plus, NPI, and BPG also 
demonstrated significant benefits for the memantine group 
compared to placebo, with either observed cases only or 
LOCF analysis.
A number of post-hoc analyses were derived from 
this study. In a subgroup analysis by Van Dyck et al, using 
several different sets of criteria as “responders”, it was found 
that there is clinically significant stabilization of symptoms 
in the memantine treated group on the SIB (P = 0.0443), 
ADCS-ADL (P = 0.0318), CIBIC-Plus (P = 0.0223), 
and NPI (P = 0.0129) with 6 out of 10 definitions of 
“responders”.41 The number needed to treat (NNT) was 
estimated to be 8 to 10. The second post-hoc analysis was a 
re-analysis of the cognitive response of the SIB to memantine 
over the 24-week period by both observed cases and LOCF 
approaches.42 The effect of memantine on the individual 
items of SIB, subscale performance and 3 post-hoc-derived 
aggregate subscales were investigated. It was shown that there 
is significantly greater improvement on memory, language, 
and praxis. In another post-hoc analysis on the behavioral 
effects of memantine using the NPI, it was found that the total 
NPI score was significantly increased in the placebo group at 
week 12 and continued to worsen at week 24, whereas NPI 
scores declined in the memantine-treated group at week 12 
and returned to baseline at week 24.43 Analyses by using 
both LOCF or observed cases produced similar conclu-
sion. Analyses of the 12 NPI domains showed significant 
differences in favor of memantine on agitation/aggression, 
irritability/lability and eating/appetite. In the final post-
hoc analysis on activities of daily living using the 19-item 
Alzheimer’s Disease Cooperative Study – Activities of 
Daily Living Inventory (ADCS-ADL-19), it was found that 
memantine-treated patients had significantly less decline 
in total ADCS-ADL-19 scores compared with placebo.44 
Specific item analysis showed benefits with memantine 
on grooming, toileting, making conversation, watching 
television, and being left alone.
In the most recently published 24-week RCT study (MEM-
MD-01) examining the efficacy and safety of memantine 
monotherapy in moderate to severe AD, 350 patients with 
probable AD by NINCDS-ADRDA diagnostic criteria were 
randomized to receive memantine (20 mg/day) or placebo.24 
The entry MMSE score range was 5 to 14. The presence of 
other psychiatric or neurologic disorders, or a Hachinski 
Ischemia Score (HIS) of greater than 4 were excluded.45 
Patients were not allowed to receive ChEI therapy within a 
month. The primary outcome measures were changes on the 
SIB and ADCS-ADL-19 from baseline to week 24. Second-
ary outcome measures included the CIBIC-Plus, NPI, FAST, 
and BGP. Prospectively defined analyses failed to reveal any 
significant benefit of memantine on the SIB or CIBIC-Plus, 
although a significant advantage was observed for memantine 
at weeks 12 and 18 with both outcome measures. None of the 
secondary measures demonstrated any significant difference 
between memantine and placebo.
Observational study of long-term 
effectiveness of memantine
In a clinical effectiveness observational study comparing 
combination therapy (memantine plus a ChEI), ChEI 
alone, and no treatment with a mean observational period 
of 30 months (mean cumulative medication treatment = 
22.5 months), it was found that the group receiving combina-
tion therapy had significantly lower mean annualized rates of 
deterioration on the Blessed Dementia Scale (BDS) and the 
Weintraub Activities of Daily Living (ADL) scores compared 
with ChEI alone (P  0.001; Cohen’s dBDS = 0.10–0.34 
and dADL = 0.23–0.46 at 1 to 2 years) and the no-treatment 
group (P  0.001; Cohen’s dBDS = 0.56–0.73 and 
dADL = 0.32–0.48 at 1 to 2 years).46–48 For the combination 
therapy group, Cohen’s d effect sizes was greater with increas-
ing treatment duration. Similar comparisons also significantly 
favored the ChEI group over the no-treatment group on the 
BDS. The authors concluded that combination therapy may 
be more effective at slowing cognitive and functional decline 
in AD compared with ChEI monotherapy and no treatment.
Safety and tolerability
Memantine is generally well tolerated. While the frequency 
of adverse events was high in the 4 RCTs, there were no 
significant differences between memantine treatment and 
placebo in the number of patients suffering least 1 adverse 
event. Agitation occurred less commonly as an adverse event 
in all studies in those taking memantine compared to those 
taking placebo (OR = 0.6, 95% CI 0.42 to 0.86, P = 0.005). 
There were no other consistent differences in specific adverse 
events between memantine and placebo.21,22 Discontinuations 
due to adverse events were fewer in the memantine groups Neuropsychiatric Disease and Treatment 2009:5 558
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than in placebos (7.4% vs 12.4%).23 Furthermore, incidence 
of gastrointestinal adverse events was lower in the memantine 
plus donepezil group compared with the placebo plus 
donepezil group. This result led to the speculation that 
memantine treatment may ameliorate some of the gastroin-
testinal adverse effects associated with ChEIs.23
In an analysis of the pooled data for tolerability and 
safety from 6 double-blind RCTs (3 in mild to moderate AD 
and 3 in moderate to severe AD) and 4 open-label exten-
sions period of those studies (2 in mild to moderate AD and 
2 in moderate to severe AD), it was found that the safety 
and tolerability profile of memantine was more favorable 
compared to placebo group.49 The adverse events most often 
reported in both placebo-treated and memantine-treated 
patients included agitation (12% vs 7.5%, respectively), 
falls (7.1% vs 6.8%), dizziness (5.7% vs 6.3%), accidental 
injury (7.2% vs 6%), influenza-like symptoms (5.8% vs 6%), 
headache (3.7% vs 5.2%), and diarrhea (5.6% vs 5%).
In a study of 3 different dosing schedules of memantine 
(i. 20 mg once daily with a 1-step up-titration, ii. 20 mg once 
daily with a 3-step up-titration, and iii. 10 mg twice daily with 
a 3-step up-titration) in a 12-week RCT study of 78 patients 
with moderate to severe AD, it was found that once-daily 
dosing and twice-daily dosing of memantine are similar in 
terms of safety and tolerability.50 Despite the relatively small 
number of subjects in each group, the number of withdrawals 
due to adverse events was low, and the adverse event were 
only mild to moderate.
The tolerability of switching from a ChEI to memantine 
has been evaluated in a study with an 8-week follow-up period 
in 46 moderate to severe AD patients switching from stable 
donepezil to memantine.51 The study concluded memantine 
was well tolerated, with a similar adverse event profile 
regardless of whether donepezil was discontinue abruptly or 
stepwise (decrease of 5 mg/day donepezil over 2 weeks).
Behavioral and psychological  
effects of memantine
Several studies have examined the behavioral and psychologi-
cal benefits of memantine.43,52–56 However, these studies used 
data collected from previously reported clinical trials, and 
therefore are not independent from each other. Gauthier et al 
investigated the effect of memantine on the behavioral symp-
toms in AD in a pooled analysis of 6 RCTs.52 The outcome 
was based on NPI scores, which were defined by 2 categories: 
(1) symptom improvement: assessed in patients who displayed 
the symptom at baseline, and (2) symptom emergence: 
assessed in patients who did not have the symptom at base-
line. The pooled study population from the 6 RCTs consists 
of 2311 patients (1242 patients were memantine-treated 
and 1069 patients were placebo-treated).22–24,57–59 The mean 
baseline MMSE was 12. The result showed significant 
improvements in total NPI scores in memantine-treated 
patients compared to placebo with LOCF analyses at week 12 
(P = 0.001) and week 24/28 (P = 0.008). In the single NPI 
item analyses, there were significant benefits with memantine 
on symptoms of delusion (P = 0.07 at week 12, P = 0.01 at 
week 24/28), hallucinations (P = 0.037 at week 12, number 
not reported at week 24/28), agitation/aggression (P = 0.001 
at week 12, P = 0.001 at week 24/28), and irritability/lability 
(P = 0.005 at week 24/28). Analysis of symptom emergence 
also indicated that memantine-treated patients had a lower 
incidence of agitation/aggression (P = 0.002), delusion 
(P = 0.047), and disinhibition (P = 0.011) at week 12 and 
of agitation/aggression (P = 0.002), irritability/lability 
(P = 0.004) and night-time behavior (P = 0.05) at week 24/28. 
The results of the analysis of only observed cases produced 
similar findings.
Maidment et al performed a meta-analysis of NPI scores 
from 5 RCT studies.54 The pooled study population included a 
total of 1750 patients, with 868 patients treated with meman-
tine and 882 patients treated with placebo.22–24,57,58 Memantine 
was significnantly better than placebo on NPI outcome in 
2 studies.23,57 The NPI change score non-significantly favored 
memantine in another 2 RCTs, and non-significantly favored 
placebo in a 1 trial.22,24,58 Using a random effects model, it was 
concluded that memantine significantly reduced the total 
mean NPI score (–1.99; 95% CI –0.08 to –3.91; P = 0.041), 
although the effect size was relatively small.
Wilcock et al performed another pooled analysis of 
memantine on moderate to severe AD to evaluate the effects 
of memantine on the behaviorally disturbed population 
(BDP).53 A total of 593 patients (306 patients receiving 
memantine and 287 patients receiving placebo) from thre 
RCTs were analyzed.22–24 The BDP was defined as any patient 
who had symptoms on any of the 3 NPI items of agitation/
aggression, delusions, or hallucinations at baseline. The 
results revealed a significant benefit for memantine compared 
to placebo on the NPI cluster (agitation/aggression, delusions 
and hallucinations) score at both week 12 (p = 0.0014) 
and week 24/28 (P = 0.0004). In addition, placebo-treated 
patients in this population demonstrated an accelerated 
disease progression for global (CIBIC-Plus Caregiver Input), 
cognitive (SIB), and functional (ADCS-ADL-19) outcomes 
compared to memantine-treated patients. However, in a 
secondary analysis of the 3 individual NPI items, only the Neuropsychiatric Disease and Treatment 2009:5 559
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item of agitation/aggression demonstrated a significant 
improvement in patients receiving memantine compared 
with those receiving placebo at week 12 (55.3% vs 43.1%; 
P = 0.011) and week 24/28 (61% vs 45%; p  0.001). 
In patients who were asymptomatic at baseline, significantly 
fewer memantine treated patients went on to develop these 
symptoms at week 12 (20.3% vs 31.9%; P = 0.10) and week 
24/28 (24.2% vs 37%; P = 0.007).
A recent study from the French national healthcare 
database examined the use of psychotropic medications 
before and after the initiation of memantine of 4600 patients.60 
Prior to initiation of memantine, there was a trend for increas-
ing psychotropic drug use as the disease progress. However, 
after initiation of memantine, the proportion of psychotropic 
drug use remained stable. This change in the trend was 
statistically significantly (P  0.001).
Discussion
Based on the current evidence, memantine treatment 
diminishes the rate of cognitive decline in patients with 
moderate to severe AD and is well tolerated. Furthermore, 
memantine treatment showed significant benefits in reduc-
ing behavioral disturbances on agitation/aggression as 
well as minimizing concomitant psychotropics use.53,56,60 
Combination therapy with another ChEI may be more effica-
cious in slowing cognitive and functional decline than ChEI 
monotherapy.23,46,61,62 Most RCTs of memantine in moderate 
to severe AD patients to date have demonstrated benefits in 
improving or stabilizing cognitive outcomes demonstrated 
in the SIB and CIBIC+, although functional outcomes 
measures are more variable.63 However, at least one study 
failed to show any sustained effects for the duration of the 
follow-up period.24
Despite the RCT evidence of efficacy of memantine, 
it remains difficult to translate significant differences on 
research measures into clinically relevant differences for 
patients and their families. A numeric change on cognitive 
measures may not fully reflect the impact on functioning of 
the patients. More sensitive instruments to assess clinically 
meaningful improvements in dementia treatments are being 
developed.64–67 Further education for the public on translation 
of research findings and implications of clinical studies may 
also improve understanding and public acceptance.
Many studies have been devoted to cost-effectiveness. 
A study in Canada by Gagnon et al evaluated the 
cost-effectiveness of memantine compared with standard 
care (without ChEIs) in moderate to severe AD.68 It was 
found that memantine monotherapy saved more than 
a month of complete dependence and produced 0.03 
additional quality-adjusted life years (QALYs), with no 
additional cost. Results are consistent with those of other 
economic evaluations of memantine performed in the US 
and Europe.39,69–72 However, these studies employed different 
methods to determine the potential value of treatment, and 
there is still a lack of consensus on how to measure quality 
of life among demented people and their caregivers. Some 
have even argued that using QALY-based measurements may 
not be appropriate for people with dementia.73 Furthermore, 
most of the currently reported RCTs are short term, with the 
longest study lasting only up to 28 weeks; thus the true long-
term efficacy of memantine for a slowly progressive disease 
such as AD remains to be confirmed. On the other hand, the 
safety and tolerability profile of memantine in clinical use has 
been excellent, with relatively few adverse events.49 There are 
no significant interactions with drugs metabolized by cyto-
chrome P450. For patients who experienced adverse effects 
or could not tolerate any ChEIs, memantine monotherapy 
can be an option and may still offer some benefits.
In conclusion, memantine is currently the only agent 
approved for treatment in patients with moderate to severe 
AD. It can be used as a monotherapy or in combination with 
other ChEIs. There are consistent clinical benefits demon-
strated on cognition, global functioning, and neurobehavioral 
symptoms. In earlier stages of AD, however, the effect of 
memantine is unclear. Moreover, there is uncertainty about 
the most appropriate time to discontinue treatment. When 
evaluating treatment response of memantine in a patient, 
it is also important to ask whether caregivers experienced 
any improvement in their own quality of life or their stress. 
More studies with longer duration of treatment and more 
transparent economic analyses will be helpful in determining 
the long-term benefits of memantine in treatment of AD.
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